Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations

Frontiers in Oncology
Athanasios PouptsisChara Stavraka

Abstract

Hereditary breast cancer accounts for 5%-10% of breast cancer cases. The majority of familial cases have been linked to germline mutations in BRCA1 and BRCA2 genes, though other high penetrance susceptibility genes have also been identified through genomic testing advances. Optimal surgical treatment for these patients, who are of a younger age, has several challenges as it usually involves aggressive therapeutic and risk reducing interventions. At the same time, the therapeutic armamentarium for BRCA1/2 mutation carriers apart from platinum salts, has been enriched with the addition of poly-ADP ribose polymerase (PARP) inhibitors with promising outcomes. In this review we provide a succinct and comprehensive overview of the surgical and systemic treatment options for patients with BRCA1/2 mutation related breast cancer and an update on the most recent systemic treatment advances.

References

Mar 10, 2001·Molecular Cell·M E MoynahanM Jasin
Jul 21, 2001·The New England Journal of Medicine·H Meijers-HeijboerJ G Klijn
Nov 8, 2001·Journal of the National Cancer Institute·L C HartmannR B Jenkins
May 25, 2002·The New England Journal of Medicine·Noah D KauffKenneth Offit
Feb 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy R RebbeckBarbara L Weber
Sep 3, 2004·Nature Reviews. Cancer·Steven A Narod, William D Foulkes
Aug 20, 2005·Nature Reviews. Cancer·William G Kaelin
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan Ashworth
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz ByrskiSteven Narod
Sep 3, 2010·JAMA : the Journal of the American Medical Association·Susan M DomchekTimothy R Rebbeck
Sep 6, 2011·Oncogene·L GalluzziG Kroemer
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Jun 21, 2013·Breast Cancer Research and Treatment·D Gareth R EvansAnthony Howell
Feb 26, 2014·Breast Cancer Research and Treatment·Antonis ValachisPehr Lind
Feb 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amy P M FinchSteven A Narod
Jun 21, 2014·International Journal of Cancer. Journal International Du Cancer·Bernadette A M Heemskerk-GerritsenCaroline Seynaeve
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod
Sep 5, 2014·Breast Cancer Research and Treatment·Martin P NilssonNiklas Loman
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J IsakoffLeif W Ellisen
Feb 4, 2016·The New England Journal of Medicine·Lynn C Hartmann, Noralane M Lindor
Sep 8, 2016·Journal of the National Cancer Institute·Joanne KotsopoulosUNKNOWN Hereditary Breast Cancer Clinical Study Group
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Jun 21, 2017·JAMA : the Journal of the American Medical Association·Karoline B KuchenbaeckerHåkan Olsson
Apr 6, 2018·The Cochrane Database of Systematic Reviews·Nora E CarbineHenry Ko
Aug 16, 2018·The New England Journal of Medicine·Jennifer K LittonJoanne L Blum
Dec 20, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas C TurnerUNKNOWN ABRAZO Study Group
Mar 22, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah A Cook, Anna V Tinker

❮ Previous
Next ❯

Citations

Feb 3, 2021·International Journal of Molecular Sciences·Cristina Herrera-ParienteLeticia Moreira
Dec 22, 2020·Frontiers in Oncology·Anne GrabenstetterGulisa Turashvili

❮ Previous
Next ❯

Software Mentioned

GeparSixto
EMBRACA

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.